{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:42Z","timestamp":1760189562900},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12931-017-0587-9","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T13:48:31Z","timestamp":1496152111000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?"],"prefix":"10.1186","volume":"18","author":[{"given":"Junghyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Goo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Ha","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Yong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Ock","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun-Gyu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoonki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myoung Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Gyu","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Suck","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Do","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"587_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease(GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. Available from: \nhttp:\/\/www.goldcopd.org\/\n\n. 2016."},{"issue":"1","key":"587_CR2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1183\/09031936.06.00024505","volume":"27","author":"KR Chapman","year":"2006","unstructured":"Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188\u2013207.","journal-title":"Eur Respir J"},{"issue":"2","key":"587_CR3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1183\/09031936.06.00025805","volume":"27","author":"AD Lopez","year":"2006","unstructured":"Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397\u2013412.","journal-title":"Eur Respir J"},{"issue":"4","key":"587_CR4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"587_CR5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1445-5994.2003.00485.x","volume":"33","author":"DW Reid","year":"2003","unstructured":"Reid DW, Soltani A, Johns DP, Bish R, Williams TJ, Burns GP, Walters EH. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J. 2003;33:572\u20137.","journal-title":"Intern Med J"},{"key":"587_CR6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","volume":"58","author":"PM Calverley","year":"2003","unstructured":"Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58:659\u201364.","journal-title":"Thorax"},{"issue":"7","key":"587_CR7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S2213-2600(13)70086-9","volume":"1","author":"PM Calverley","year":"2013","unstructured":"Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013;1(7):564\u201373.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"587_CR8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.10-2974","volume":"140","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Celli BR, Donohue JF, Martin UJ. Bronchodilator reversibility in COPD. Chest. 2011;140(4):1055\u201363.","journal-title":"Chest"},{"key":"587_CR9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","volume":"115","author":"DA Mahler","year":"1999","unstructured":"Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of Salmeterol Xinafoate in the treatment of COPD. Chest. 1999;115:957\u201365.","journal-title":"Chest"},{"key":"587_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1465-9921-12-127","volume":"12","author":"M Hardin","year":"2011","unstructured":"Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP, Investigators CO. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.","journal-title":"Respir Res"},{"issue":"2","key":"587_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1378\/chest.13-0622","volume":"145","author":"AM Menezes","year":"2014","unstructured":"Menezes AM, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muino A, Jardim JR, Valdivia G, Talamo C, Team P. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297\u2013304.","journal-title":"Chest"},{"issue":"4","key":"587_CR12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1378\/chest.14-2413","volume":"148","author":"H Ward","year":"2015","unstructured":"Ward H, Cooper BG, Miller MR. Improved criterion for assessing lung function reversibility. Chest. 2015;148(4):877\u201386.","journal-title":"Chest"},{"issue":"5","key":"587_CR13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1164\/ajrccm\/144.5.1202","volume":"144","author":"American Thoracic Society","year":"1991","unstructured":"American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202\u201318.","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"587_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.65.5.552","volume":"65","author":"Report of the Committee on Emphysema American College of Chest Physicians","year":"1974","unstructured":"Report of the Committee on Emphysema American College of Chest Physicians. Criteria for the assessment of reversibility in airways obstruction. Chest. 1974;65(5):552\u20133.","journal-title":"Chest"},{"issue":"9","key":"587_CR15","first-page":"331","volume":"48","author":"JJ Soler-Catalu\u02dcna","year":"2012","unstructured":"Soler-Catalu\u02dcna JJ, Cos\u00edo B, Izquierdo JL, L\u00f3pez-Campos JL, Mar\u00edn JM, Ag\u00fcero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, Gonz\u00e1lez MC, Miravitlles M, Mons\u00f3 E, Montemayor T, Morera J, Ortega F, Peces-Barba G, Puente L, Rodr\u00edguez JM, Sala E, Sauleda J, Soriano JB, Viejor JL. Consensus Document on the Overlap Phenotype COPD\u2013Asthma in COPD. Arch Bronconeumol. 2012;48(9):331\u20137.","journal-title":"Arch Bronconeumol"},{"key":"587_CR16","unstructured":"Diagnosis of Diseases of Chronic Airflow Limitation:Asthma, COPD and Asthma-COPD Overlap Syndrome(ACOS). Updated 2015. Available from: \nhttp:\/\/www.goldcopd.org\/\n\n. 2015."},{"issue":"8","key":"587_CR17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1183\/09031936.95.08081398","volume":"8","author":"NM Siafakas","year":"1995","unstructured":"Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8(8):1398\u2013420.","journal-title":"Eur Respir J"},{"issue":"2","key":"587_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET. Standardisation of spirometry. Eur Respir J. 2005;26(2):319\u201338.","journal-title":"Eur Respir J"},{"key":"587_CR19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1378\/chest.80.1.97","volume":"80","author":"BE Pennock","year":"1981","unstructured":"Pennock BE, Rogers RM, McCaffree R. Changes in measured spirometric indices. Chest. 1981;80:91\u20139.","journal-title":"Chest"},{"key":"587_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1164\/arrd.1983.128.1.153","volume":"128","author":"RL Sourk","year":"1983","unstructured":"Sourk RL, Nugent KM. Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis. 1983;128:153\u20137.","journal-title":"Am Rev Respir Dis"},{"issue":"8","key":"587_CR21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.rmed.2014.05.006","volume":"108","author":"JM Marin","year":"2014","unstructured":"Marin JM, Ciudad M, Moya V, Carrizo S, Bello S, Piras B, Celli BR, Miravitlles M. Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. Respir Med. 2014;108(8):1180\u20138.","journal-title":"Respir Med"},{"key":"587_CR22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1164\/ajrccm.162.5.9910112","volume":"162","author":"A Papi","year":"2000","unstructured":"Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri LM. Partial Reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1773\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"587_CR23","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1378\/chest.108.6.1568","volume":"108","author":"P Weiner","year":"1995","unstructured":"Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled Budesonide therapy for patients with stable COPD. Chest. 1995;108:1568\u201371.","journal-title":"Chest"},{"issue":"5","key":"587_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","volume":"29","author":"R Siva","year":"2007","unstructured":"Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906\u201313.","journal-title":"Eur Respir J"},{"issue":"4","key":"587_CR25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2009.10.024","volume":"104","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Lee YK, Kim E-K, Kim T-H, Huh JW, Kim WJ, Lee JH, Lee S-M, Lee S, Lim SY, Shin TR, Yoon HI, Sheen SS, Kim N, Seo JB, Oh Y-M, Lee SD. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104(4):542\u20139.","journal-title":"Respir Med"},{"issue":"6","key":"587_CR26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.arbres.2011.01.016","volume":"47","author":"M Miravitlles","year":"2011","unstructured":"Miravitlles M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol. 2011;47(6):271\u20133.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"587_CR27","doi-asserted-by":"crossref","first-page":"e001838-e","DOI":"10.1136\/bmjopen-2012-001838","volume":"3","author":"RL DiSantostefano","year":"2013","unstructured":"DiSantostefano RL, Li H, Rubin DB, Stempel DA. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open. 2013;3(4):e001838-e.","journal-title":"BMJ Open"},{"issue":"9795","key":"587_CR28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(11)61047-7","volume":"378","author":"FJ Martinez","year":"2011","unstructured":"Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development. Lancet. 2011;378(9795):1027\u201337.","journal-title":"Lancet"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-017-0587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T13:49:01Z","timestamp":1496152141000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-017-0587-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1186\/s12931-017-0587-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]},"article-number":"107"}}